NDC Package 25682-016-12 Strensiq

Asfotase Alfa Solution Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
25682-016-12
Package Description:
12 VIAL in 1 CARTON / 1 mL in 1 VIAL (25682-016-01)
Product Code:
Proprietary Name:
Strensiq
Non-Proprietary Name:
Asfotase Alfa
Substance Name:
Asfotase Alfa
Usage Information:
STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
11-Digit NDC Billing Format:
25682001612
Billing Unit:
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
NDC to RxNorm Crosswalk:
  • RxCUI: 1720263 - asfotase alfa 18 MG in 0.45 ML Injection
  • RxCUI: 1720263 - 0.45 ML asfotase alfa 40 MG/ML Injection
  • RxCUI: 1720263 - asfotase alfa 18 MG per 0.45 ML Injection
  • RxCUI: 1720268 - Strensiq 18 MG in 0.45 ML Injection
  • RxCUI: 1720268 - 0.45 ML asfotase alfa 40 MG/ML Injection [Strensiq]
  • Product Type:
    Human Prescription Drug
    Labeler Name:
    Alexion Pharmaceuticals, Inc.
    Dosage Form:
    Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
    Administration Route(s):
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
  • Active Ingredient(s):
    Sample Package:
    No
    FDA Application Number:
    BLA125513
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    10-23-2015
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 25682-016-12?

    The NDC Packaged Code 25682-016-12 is assigned to a package of 12 vial in 1 carton / 1 ml in 1 vial (25682-016-01) of Strensiq, a human prescription drug labeled by Alexion Pharmaceuticals, Inc.. The product's dosage form is solution and is administered via subcutaneous form.

    Is NDC 25682-016 included in the NDC Directory?

    Yes, Strensiq with product code 25682-016 is active and included in the NDC Directory. The product was first marketed by Alexion Pharmaceuticals, Inc. on October 23, 2015 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 25682-016-12?

    The contents of this package are billed per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.

    What is the 11-digit format for NDC 25682-016-12?

    The 11-digit format is 25682001612. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-225682-016-125-4-225682-0016-12